LENZ Therapeutics (LENZ) FCF Margin (2025 - 2026)

LENZ Therapeutics (LENZ) posted quarterly FCF Margin of 1766.49% for Q1 2026, down 784.98% quarter-over-quarter from 257.89% in Q4 2025.

LENZ Therapeutics (LENZ) FCF Margin (2025 - 2026) Analysis & Trends

LENZ Therapeutics (LENZ) has reported FCF Margin for 2 consecutive years, with 1766.49% the latest figure, recorded in Q1 2026.

In Q1 2026, FCF Margin changed N/A year-over-year to 1766.49%; the TTM figure through Mar 2026 stood at 1254.77% (changed N/A YoY), while the FY2025 annual figure was 1383.4%, changed N/A from the prior year.
FCF Margin declined to 1766.49% in Q1 2026 per LENZ's latest filing, from 257.89% in the prior quarter.
Across five years, FCF Margin topped out at 257.89% in Q4 2025 and bottomed at 1766.49% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	13.35%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	22.62%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	41.07%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	70.82%
10	LENZ Therapeutics	147.30 Mn	147.30 Mn	5.21 Mn	-705.96%

Download Data